Endoscopic approach for diagnosing autoimmune pancreatitis

Terumi Kamisawa, Hajime Anjiki, Kensuku Takuma, Naoto Egawa, Takao Itoi, Fumihide Itokawa

Abstract

It is of utmost importance to differentiate autoimmune pancreatitis (AIP) from pancreatic cancer (PC). Segmental AIP cases are sometimes difficult to differentiate from PC. On endoscopic retrograde cholangiopancreatography, long or skipped irregular narrowing of the main pancreatic duct (MPD), less upstream dilatation of the distal MPD, side branches derived from the narrowed portion of the MPD, absence of obstruction of the MPD, and stenosis of the intrahepatic bile duct suggest AIP rather than PC. Abundant infiltration of IgG4-positive plasma cells is frequently and rather specifically detected in the major duodenal papilla of AIP patients. IgG4-immunostaining of biopsy specimens obtained from the major duodenal papilla is useful for supporting a diagnosis of AIP with pancreatic head involvement. On endoscopic ultrasonography (EUS), hyperechoic spots in the hypoechoic mass and the duct-penetrating sign suggest AIP rather than PC. EUS and intraductal ultrasonography sometimes show wall thickening of the common bile duct even in the segment in which abnormalities are not clearly observed with cholangiography in AIP patients. EUS-guided fine needle aspiration, especially EUS-guided Tru-Cut biopsy, is useful to diagnose AIP, as well as to exclude PC.

INTRODUCTION

Autoimmune pancreatitis (AIP) is a recently identified clinical entity of pancreatitis in which it is suspected that autoimmune mechanisms are involved in the pathogenesis. AIP is characterized clinically by elderly male preponderance, frequent initial symptom of obstructive jaundice without pain, occasional association with impaired pancreatic endocrine or exocrine function, various extrapancreatic lesions, and a favorable response to steroid therapy. AIP is characterized radiologically by irregular narrowing of the main pancreatic duct (MPD) and enlargement of the pancreas; and serologically by elevation of serum IgG, or IgG4 levels, and the presence of some autoantibodies. Histopathological characteristics are dense lymphoplasmacytic infiltration with fibrosis and obliterative phlebitis in the pancreas[1-3]. Since there is currently no diagnostic serological marker, and as it is usually difficult to take adequate specimens from the pancreas, AIP is currently diagnosed based on a combination of clinical, laboratory, and imaging studies[4-6]. In 2006, the Japan Pancreas Society proposed the “Clinical
Diagnostic Criteria for Autoimmune Pancreatitis. It contained three items: (1) radiological imaging showing diffuse or localized enlargement of the pancreas and diffuse or segmental irregular narrowing of the MPD; (2) laboratory data showing abnormally elevated levels of serum gammaglobulin, IgG or IgG4, or the presence of autoantibodies; and (3) histological findings showing marked interlobular fibrosis and prominent lymphoplasmacytic infiltration in the pancreas. To make the diagnosis of AIP, criterion 1 is mandatory, and either criterion 2 or criterion 3 must be present.

AIP responds dramatically to steroid therapy and therefore to avoid unnecessary surgery, an accurate diagnosis of AIP is required. The most important disease that should be differentiated from AIP is pancreatic cancer (PC). Serum IgG4 levels are elevated most frequently in AIP patients. However, the sensitivity of elevated serum IgG4 levels in AIP patients is reported to be 73%-80% [9], and elevation of serum IgG4 level is detected in some cases of PC [10,11]. In particular, AIP forming a mass-like lesion in the head of the pancreas is sometimes difficult to differentiate from locally advanced pancreatic head cancer. Based on our experience with 50 cases of AIP, this review focuses on the endoscopic approach for diagnosing AIP, with special emphasis on differentiating AIP from PC.

ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY

Diffuse irregular narrowing of the MPD on endoscopic retrograde cholangiopancreatography (ERCP) is one of the radiological features rather specific to AIP (Figure 1). PC rarely shows this pancreatogram. However, some AIP patients show segmental narrowing of the MPD (Figure 2A), which is rather difficult to differentiate from stenosis of the MPD in PC. In our series [12], the length of the narrowed portion of the MPD on endoscopic retrograde pancreatography (ERP) was 6.7 ± 3.2 (mean ± SD) cm in AIP patients, which was significantly longer than in PC patients (2.6 ± 0.8 cm; P < 0.001). The length of the narrowed portion of the MPD on ERP was longer than 3 cm in 76% of AIP patients, which was significantly higher than in PC patients (20%; P < 0.001). In AIP patients, the degree of narrowing of the MPD varied in the same patient, and skipped, narrowed lesions of the MPD were detected in 35% of our AIP patients, but in none of our PC patients (P < 0.001). In AIP patients with segmental narrowing of the MPD, upstream dilatation of the distal MPD was less often noted than in PC. The maximal diameter of the upstream MPD on ERP was 2.9 ± 0.7 mm in segmental AIP patients, which was significantly smaller than in pancreatic head cancer patients (7.1 ± 1.9 mm; P < 0.001). The maximal diameter of the upstream MPD was smaller than 5 mm in 94% of segmental AIP patients, significantly higher than in PC patients (18%; P < 0.001). Side branches were more frequently derived from the narrowed portion of the MPD in AIP patients (65%) than in PC patients (25%; P < 0.036). Obstruction of the MPD was detected more often in PC patients (60%) than in AIP patients (6%; P < 0.001).

On endoscopic retrograde cholangiography, stenosis of the lower bile duct was detected frequently in both AIP and PC patients (Figure 2A). Brushing cytology of the stenotic biliary lesion and cytology of the bile via an endoscopic nasobiliary drainage tube inserted to manage jaundice, are useful to differentiate AIP from pancreatic or biliary cancer. Stenosis of the intrahepatic bile duct was detected in a few AIP patients, but it was not detected in PC patients. When AIP patients develop stenosis in the intrahepatic bile duct, the cholangiographic appearance is similar to that of primary sclerosing cholangitis.
A long stricture was detected in the hepatic hilar region in AIP patients involving the intrahepatic bile ducts, but the diffusely distributed, beaded and pruned-tree appearance, that is usually detected in PSC patients was not detected in AIP patients. Stenosis of the hilar bile duct in AIP patients should be also differentiated from cholangiocarcinoma at the hepatic hilus, these diseases can be differentiated by the absence of the pancreatic abnormalities in patients with cholangiocarcinoma at the hepatic hilus.

Both pancreatic and biliary lesions improve 2-4 wk after starting oral steroid therapy (initial prednisolone dose: 30 mg/d) (Figure 2B). A poor response to steroid therapy should raise the possibility of PC and the need for re-evaluation of the diagnosis.

**ENDOSCOPIC OBSERVATION AND BIOPSY OF THE MAJOR DUODENAL PAPILLA**

The major duodenal papilla is sometimes swollen in AIP patients. In our series, swelling of the major duodenal papilla was detected endoscopically in 24% (12/50) of AIP patients. Histologically, dense lymphoplasmacytic infiltration and fibrosis is detected in the swollen major duodenal papilla (Figure 3A), similar to that seen in the pancreas of AIP patients. Furthermore, abundant infiltration of IgG4-positive plasma cells in the papilla is frequently and specifically detected in AIP patients. In our study of IgG4-immunostaining in biopsy specimens from the major duodenal papilla, severe infiltration of IgG4-positive plasma cells ($\geq 10/HPF$) was observed in the major duodenal papilla of all 8 AIP patients with pancreatic head involvement (Figure 3B). Moderate infiltration of IgG4-positive plasma cells (9-4/HPF) was detected in 1 patient with pancreatic head cancer, but there were also rare (3-5/HPF) IgG4-positive plasma cells infiltrating the major duodenal papilla in 2 AIP patients who only had pancreatic body and/or tail involvement, in 9 patients with pancreatic cancer, and in 10 patients with papillitis. IgG4-immunostaining of biopsy specimens obtained from the major duodenal papilla is useful for supporting a diagnosis of AIP with pancreatic head involvement. After steroid therapy, the swollen major duodenal papilla decreases on endoscopy, and the number of IgG4-positive plasma cells in repeat biopsy specimens from the major duodenal papilla decreases.

**ENDOSCOPIC ULTRASONOGRAPHY AND INTRADUCTAL ULTRASONOGRAPHY**

Endoscopic ultrasonography (EUS) imaging of AIP shows hypoechoic enlargement of the pancreas with hypoechoic spots. A lobular outer gland margin of the pancreas or a hyperechoic pancreatic ductal margin, which is frequently detected in alcoholic chronic pancreatitis, is rarely observed in AIP patients. A hypoechoic mass lesion detected in segmental AIP patients is difficult to differentiate from PC (Figure 4A). Hyperechoic spots in a hypoechoic mass and the duct-penetrating sign suggest AIP rather than PC. Hyperechoic spots may correspond to compressed pancreatic ducts. The lower bile duct, corresponding to the stenotic portion on ERCP, shows marked wall thickening with a smooth configuration of the outermost layer on EUS and intraductal ultrasonography (IDUS). This finding suggests that the bile duct wall thickening itself causes the biliary stenosis, and that it is not caused by extrinsic compression from inflamma-
tory pancreatic tissue in AIP. EUS and IDUS sometimes show wall thickening of the common bile duct even in the segment in which abnormalities are not clearly observed on cholangiography in AIP patients (Figure 5)\[19\].

ENDOSCOPIC ULTRASONOGRAPHY-GUIDED FINE NEEDLE ASPIRATION AND ENDOSCOPIC ULTRASONOGRAPHY-GUIDED TRU-CUT BIOPSY

Endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) can be safely performed at the same time as diagnostic EUS, and it will become an established technique to evaluate pancreatic masses. In segmental AIP cases, EUS-FNA is useful to exclude the possibility of PC. The presence of cellular stromal fragments with prominent lymphocytosis either within the stroma or in the background can support a clinical diagnosis of AIP (Figure 4B)\[20\]. Furthermore, the presence of many IgG4-positive plasma cells in the aspirated specimen examined by IgG4-immunostaining provides more support for the diagnosis of AIP. However, cytological examination of EUS-FNA specimens is sometimes insufficient for diagnosing AIP due to the small sample and lack of tissue architecture. To overcome the limitations of needles which only allow cytological review, large caliber cutting biopsy needles have been developed that acquire samples in which tissue architecture can be assessed and histological examination performed. Endoscopic ultrasonography-guided Tru-Cut biopsy (EUS-TCB) acquires core specimens that preserve tissue architecture and permit histological review and diagnosis of AIP. Histological features vary, but the most common finding is fibrosis and an intense inflammatory cell infiltrate comprised mostly of lymphocytes and plasma cells, usually surrounding medium- and large-sized interlobular ducts accompanied by an obliterator phlebitis predominantly involving venules. According to a Mayo Clinic study, TCB specimens were considered diagnostic or strongly suggestive in 12/14 AIP patients\[20\].

CONCLUSION

It is most important to differentiate AIP from PC. Long or skipped narrowed portions with side branches of the main pancreatic duct without upstream dilatation, and stenosis of the intrahepatic bile duct on ERCP suggest AIP rather than PC. IgG4-immunostaining of biopsy specimens obtained from the major duodenal papilla is useful for supporting a diagnosis of AIP with pancreatic head involvement. On EUS, hyperechoic spots in a hypoechoic mass and the duct-penetrating sign suggest AIP rather than PC. EUS-FNA, especially EUS-TCB, is useful to diagnose AIP, as well as to exclude PC.

REFERENCES

1. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006; 41: 613-625
2. Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med 2006; 355: 2670-2676
3. Gardner TB, Chari ST. Autoimmune pancreatitis. Gastroenterol Clin North Am 2008; 37: 459-460, vii
4. Okazaki K, Kawa S, Kamisawa T, Naruse S, Tanaka S, Nishimori I, Ohara H, Ito H, Ito T, Kiyama S, Inui K, Shimosegawa T, Koizumi M, Suda K, Shiratori K, Yamaguchi K, Sugarim T, Sugiyama M, Otsuki M. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 2006; 41: 626-631
5. Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS, Farnell MB. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4: 1010-1016, quiz 934
6. Kim KP, Kim MH, Kim JC, Lee SS, Seo DW, Lee SK. Diagnostic criteria for autoimmune chronic pancreatitis revisited. World J Gastroenterol 2006; 12: 2487-2496
7. Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003; 98: 2694-2699
8. Choi EK, Kim MI, Lee TY, Kwon S, Oh IC, Hwang CY, Seo DW, Lee SS, Lee SK. The sensitivity and specificity of serum immunoglobulin G and immunoglobulin G4 levels in the diagnosis of autoimmune chronic pancreatitis: Korean experience. Pancreas 2007; 35: 156-161
9. Kamisawa T, Imai M, Egawa N, Tsuruta K, Okamoto A. Serum IgG4 levels and extrapancreatic lesions in autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2008; 20: 1167-1170
10. Ghazale A, Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Clain JE, Pearson RK, Peltaez-Luna M, Petersen BT, Vege SS, Farnell MB. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646-1653
11. Raina A, Krasinskas AM, Greer JB, Lamb J, Fink E, Moser AJ, Zeh HJ 3rd, Slivka A, Whitcomb DC. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132: 48-53
12. Kamisawa T, Imai M, Yui Chen P, Tu Y, Egawa N, Tsuruta K, Okamoto A, Suzuki M, Kamata N. Strategy for differentiating autoimmune pancreatitis from pancreatic cancer. Pancreas 2008; 37: e62-e67
13. Nakazawa T, Ohara H, Sano H, Aoki S, Kobayashi S, Okamoto T, Imai H, Nomura T, Joh T, Itoh M. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 2004; 60: 937-944
14. Kamisawa T, Egawa N, Tsuruta K, Okamoto A, Furuta N. Primary sclerosing cholangitis may be overestimated in...
Kamisawa T et al. Endoscopic approach for diagnosing autoimmune pancreatitis

15 Unno H, Saegusa H, Fukushima M, Hamano H. Usefulness of endoscopic observation of the main duodenal papilla in the diagnosis of sclerosing pancreatitis. *Gastrointest Endosc* 2002; 56: 880-884

16 Kamisawa T, Tu Y, Nakajima H, Egawa N, Tsuruta K, Okamoto A. Usefulness of biopsying the major duodenal papilla to diagnose autoimmune pancreatitis: a prospective study using IgG4-immunostaining. *World J Gastroenterol* 2006; 12: 2031-2033

17 Kamisawa T, Tu Y, Egawa N, Tsuruta K, Okamoto A. A new diagnostic endoscopic tool for autoimmune pancreatitis. *Gastrointest Endosc* 2008; 68: 358-361

18 Hyodo N, Hyodo T. Ultrasonographic evaluation in patients with autoimmune-related pancreatitis. *J Gastroenterol* 2003; 38: 1155-1161

19 Hirano K, Shiratori Y, Komatsu Y, Yamamoto N, Sasahira N, Toda N, Isayama H, Tada M, Tsujino T, Nakata R, Kawase T, Katamoto T, Kawabe T, Omata M. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. *Clin Gastroenterol Hepatol* 2003; 1: 453-464

20 Deshpande V, Mino-Kenudson M, Brugge WR, Pitman MB, Fernandez-del Castillo C, Warshaw AL, Lauwers GY. Endoscopic ultrasound guided fine needle aspiration biopsy of autoimmune pancreatitis: diagnostic criteria and pitfalls. *Am J Surg Pathol* 2005; 29: 1464-1471

21 Levy MJ, Wiersema MJ, Chari ST. Chronic pancreatitis: focal pancreatitis or cancer? Is there a role for FNA/biopsy? Autoimmune pancreatitis. *Endoscopy* 2006; 38 Suppl 1: S30-S35

S- Editor Zhang HN  L- Editor Lalor PF  E- Editor Ma WH